[go: up one dir, main page]

MX2018007841A - Composicion de celula dendritica. - Google Patents

Composicion de celula dendritica.

Info

Publication number
MX2018007841A
MX2018007841A MX2018007841A MX2018007841A MX2018007841A MX 2018007841 A MX2018007841 A MX 2018007841A MX 2018007841 A MX2018007841 A MX 2018007841A MX 2018007841 A MX2018007841 A MX 2018007841A MX 2018007841 A MX2018007841 A MX 2018007841A
Authority
MX
Mexico
Prior art keywords
dendritic cell
antigen
fragment
cell composition
mhc class
Prior art date
Application number
MX2018007841A
Other languages
English (en)
Inventor
Schendel Dolores
Milosevic Slavoljub
Ellinger Christian
Wehner Carina
Original Assignee
Medigene Immunotherapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Immunotherapies Gmbh filed Critical Medigene Immunotherapies Gmbh
Publication of MX2018007841A publication Critical patent/MX2018007841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

La presente invencion contempla composiciones de celulas dendriticas. Las composiciones de celulas dendriticas emplean senales de direccionamiento MHC de clase II fusionadas a un antígeno o fragmento de este para obtener la presentacion de MHC II del antigeno o el fragmento de este. En particular, la invencion se refiere a una vacuna de celulas dendriticas que comprende celulas dendriticas que expresan una senal de direccionamiento MHC de clase II fusionada a un antigeno o fragmento de este. Tambien se describen vacunas de celulas dendriticas para la estimulacion de una respuesta inmune contra el antigeno asociado al melanoma.
MX2018007841A 2015-12-23 2016-12-22 Composicion de celula dendritica. MX2018007841A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15202329 2015-12-23
EP16190399 2016-09-23
PCT/EP2016/082445 WO2017109110A1 (en) 2015-12-23 2016-12-22 Dendritic cell composition

Publications (1)

Publication Number Publication Date
MX2018007841A true MX2018007841A (es) 2018-11-09

Family

ID=57794260

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007841A MX2018007841A (es) 2015-12-23 2016-12-22 Composicion de celula dendritica.
MX2018007842A MX2018007842A (es) 2015-12-23 2016-12-22 Nueva generacion de tcr especificos de antigeno.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018007842A MX2018007842A (es) 2015-12-23 2016-12-22 Nueva generacion de tcr especificos de antigeno.

Country Status (17)

Country Link
US (2) US10882891B2 (es)
EP (4) EP3394248B1 (es)
JP (3) JP6697562B2 (es)
KR (4) KR20200100858A (es)
CN (2) CN108473960A (es)
AU (2) AU2016374873B2 (es)
BR (2) BR112018012826A2 (es)
CA (2) CA3009564C (es)
DK (2) DK3394247T3 (es)
EA (2) EA201891460A1 (es)
ES (2) ES2863733T3 (es)
HU (1) HUE053674T2 (es)
MX (2) MX2018007841A (es)
PH (2) PH12018501335A1 (es)
PL (2) PL3394247T3 (es)
TW (2) TWI752930B (es)
WO (2) WO2017109109A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517711A (ja) 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー 細胞表面タンパク質に対する抗体を作製する方法
US10858760B2 (en) 2015-06-01 2020-12-08 Medigene Immunotherapies Gmbh T cell receptor library
BR112018012826A2 (pt) 2015-12-23 2018-12-04 Medigene Immunotherapies Gmbh método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1
CN119162251A (zh) 2017-12-04 2024-12-20 美国卫生和人力服务部 针对突变的ras的hla i类限制性t细胞受体
US11015402B2 (en) 2018-04-27 2021-05-25 Canrig Robotic Technologies As System and method for conducting subterranean operations
US10808465B2 (en) * 2018-04-27 2020-10-20 Canrig Robotic Technologies As System and method for conducting subterranean operations
AU2019289973B2 (en) * 2018-06-21 2025-09-11 Universiteit Gent Method for the in vitro differentiation and maturation of dendritic cells for therapeutic use
CN110172091B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
WO2020247510A1 (en) * 2019-06-03 2020-12-10 The Scripps Research Institute A chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy
US20230338530A1 (en) * 2020-01-10 2023-10-26 Lg Chem, Ltd. Composition comprising antigen-presenting cell co-expressing mhc and tumor antigen, and cancer treatment using same
CN112133372B (zh) * 2020-08-18 2022-06-03 北京臻知医学科技有限责任公司 抗原特异性tcr数据库的建立方法及抗原特异性tcr的评估方法
WO2022086185A1 (ko) * 2020-10-20 2022-04-28 연세대학교 산학협력단 단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법
WO2022115415A1 (en) * 2020-11-24 2022-06-02 Providence Health & Services - Oregon T cell receptors specific for a mutant form of the ret oncogene and uses thereof
WO2023060163A2 (en) * 2021-10-06 2023-04-13 Board Of Regents, The University Of Texas System Shp1 modified dendritic cells and extracellular vesicles derived therefrom and associated methods
TW202340474A (zh) * 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0500780A4 (en) 1989-11-15 1993-03-10 National Jewish Center For Immunology And Respiratory Medicine Method for measuring t-cell surface antigens in humans
JPH06502529A (ja) 1990-08-09 1994-03-24 ナショナル　ジューイッシュ　センター　フォア　イミュノロジィ　アンド　レスパラトリィ　メディスン 組換えｄｎａベクターを使用するヒトｔ細胞受容体要素に対するモノクローナル抗体の製造方法
CA2073031C (en) 1990-11-27 2002-10-01 Linda C. Burkly Anti-cd4 antibody homologs useful in prophylaxis and treatment of aids, arc and hiv infection
US5480895A (en) 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19625191A1 (de) 1996-06-24 1998-01-02 Boehringer Mannheim Gmbh Nierenkarzinom-spezifische T-Zellen
US6284879B1 (en) * 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
CA2405363A1 (en) * 2000-04-28 2001-11-08 Ctl Immunotherapies Corp. Epitope synchronization in antigen presenting cells
IL136459A0 (en) 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
FR2822846B1 (fr) 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
WO2003025020A1 (en) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Method of constructing camel antibody library
DK1558643T3 (da) 2002-11-09 2009-09-07 Immunocore Ltd Cellereceptorpr sentation
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
ES2842878T3 (es) 2005-08-05 2021-07-15 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Generación de células T específicas de antígeno
JP2007097580A (ja) 2005-09-06 2007-04-19 Shizuoka Prefecture Ｔ細胞レセプターβ鎖遺伝子
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
AU2007248019B2 (en) 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
AU2008292854A1 (en) * 2007-08-30 2009-03-05 Genentech, Inc. Methods and compositions for modulating T cells
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US8394778B1 (en) * 2009-10-08 2013-03-12 Immune Disease Institute, Inc. Regulators of NFAT and/or store-operated calcium entry
WO2011053789A2 (en) * 2009-10-30 2011-05-05 James Cameron Oliver Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
KR20130048193A (ko) 2010-03-02 2013-05-09 에프. 호프만-라 로슈 아게 발현 벡터
CN102719399A (zh) * 2012-04-28 2012-10-10 北京爱根生物科技有限公司 自体特异性t细胞的体外扩增方法及所制备的t细胞体系、体系的药物应用和组分监测方法
KR102386481B1 (ko) 2012-06-15 2022-04-14 이뮤노믹 쎄라퓨틱스, 인크. 알레르기 치료용 핵산
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CA2942433C (en) 2014-03-14 2023-08-01 Immunocore Limited Tcr libraries
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
CA2987877A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
JP2018517711A (ja) 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー 細胞表面タンパク質に対する抗体を作製する方法
US10858760B2 (en) 2015-06-01 2020-12-08 Medigene Immunotherapies Gmbh T cell receptor library
BR112018012826A2 (pt) 2015-12-23 2018-12-04 Medigene Immunotherapies Gmbh método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1

Also Published As

Publication number Publication date
KR20200085362A (ko) 2020-07-14
US10882891B2 (en) 2021-01-05
JP2020114222A (ja) 2020-07-30
JP6697562B2 (ja) 2020-05-20
BR112018012694A2 (pt) 2018-12-04
EP3394248B1 (en) 2021-02-10
DK3394248T3 (da) 2021-04-19
JP6676759B2 (ja) 2020-04-08
WO2017109109A1 (en) 2017-06-29
WO2017109110A1 (en) 2017-06-29
TW201736595A (zh) 2017-10-16
AU2016374873A1 (en) 2018-05-17
EA201891460A1 (ru) 2018-12-28
PH12018501335A1 (en) 2019-02-18
NZ741954A (en) 2020-04-24
ES2865484T3 (es) 2021-10-15
CA3009542A1 (en) 2017-06-29
EP3394247B1 (en) 2021-02-10
CN108473960A (zh) 2018-08-31
EP3901254A1 (en) 2021-10-27
MX2018007842A (es) 2018-11-09
HUE053674T2 (hu) 2021-07-28
US11155589B2 (en) 2021-10-26
US20190000949A1 (en) 2019-01-03
CN108603171A (zh) 2018-09-28
EP3394247A1 (en) 2018-10-31
TWI772282B (zh) 2022-08-01
EP3394248A1 (en) 2018-10-31
ES2863733T3 (es) 2021-10-11
AU2016374874A1 (en) 2018-05-17
PL3394248T3 (pl) 2021-09-13
CA3009564C (en) 2023-08-29
KR20200100858A (ko) 2020-08-26
CA3009542C (en) 2023-08-29
EA201891459A1 (ru) 2018-11-30
EP3889253A1 (en) 2021-10-06
JP2018538001A (ja) 2018-12-27
JP2018537999A (ja) 2018-12-27
TW201736594A (zh) 2017-10-16
AU2016374873B2 (en) 2020-12-24
PL3394247T3 (pl) 2021-08-23
KR20180089446A (ko) 2018-08-08
CA3009564A1 (en) 2017-06-29
US20190002515A1 (en) 2019-01-03
PH12018501336A1 (en) 2019-02-18
DK3394247T3 (da) 2021-04-12
KR102319839B1 (ko) 2021-11-01
KR20180093954A (ko) 2018-08-22
NZ741955A (en) 2020-04-24
AU2016374874B2 (en) 2020-12-03
BR112018012826A2 (pt) 2018-12-04
TWI752930B (zh) 2022-01-21

Similar Documents

Publication Publication Date Title
MX2018007841A (es) Composicion de celula dendritica.
AR132094A2 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
CY1124845T1 (el) Μεθοδοι παροχης μονοκλωνου rna
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
MX378913B (es) Células para inmunoterapia diseñadas para dirigir antígeno presente tanto en células inmunes y células patológicas.
CO2017000510A2 (es) Constructos de car
CL2017001819A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX2022006002A (es) Proteinas de fusion inmunomoduladoras y usos de las mismas.
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
MX2017003268A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2016014643A (es) Composiciones de insulina de rapida accion.
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
MX2016015235A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
MX2018014214A (es) Sistema de adhesivo curable de cianoacrilato en dos partes.
MX2016002166A (es) Anticuerpos.
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
MX2016006758A (es) Composiciones y metodos de vectores para inducir una respuesta inmunitaria mediante el uso de vectores de poxvirus.
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
CL2017000625A1 (es) Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos